Seeking Alpha
08 Jul 2026, 01:03 UTC · 3h ago
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
08 Jul 2026, 01:03 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ovid Therapeutics has a cash runway of $193 million extending through 2029. — Long-term solvency reduces immediate dilution risk and provides stability for clinical development.
+0.60Lead asset OV329 will begin Phase 2 trials in Q2 2026 for drug-resistant epilepsies. — The start of Phase 2 is a critical value inflection point for the company's primary product candidate.
+0.40Secondary asset OV4071 is currently in Phase 1 and targeting the schizophrenia and psychosis market. — Diversification into a high-value psychiatric market provides a secondary growth lever beyond epilepsy.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is rated a Buy due to a strong cash runway and promising clinical assets in epilepsy and schizophrenia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
